




RealRate

PHARMACEUTICAL 2021

Bellicum Pharmaceuticals INC
Rank 255 of 394



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Bellicum Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bellicum Pharmaceuticals INC compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Bellicum Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is 214%, being 43% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	39,443
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,701
Liabilities, Non-Current	0
Other Assets	952
Other Compr. Net Income	-12
Other Expenses	0
Other Liabilities	344
Other Net Income	43,970
Other Revenues	2,891
Property and Equipment	189
Research and Development	39,052
Selling, General and Administrative Expense	15,531

Output Variable	Value in 1000 USD
Assets	40,584
Liabilities	25,045
Expenses	54,583
Revenues	2,891
Stockholders Equity	15,539
Net Income	-7,722
Comprehensive Net Income	-7,728
BaseVar	83,542
ECR before LimitedLiability	80%
Economic Capital Ratio	214%